NLRC5: new cancer buster?
Feng Tang1,2, Yadi Xu3,4, Bing Zhao5,6
1Department of Neurosurgery, The Second Affiliated Hospital of Anhui Medical University, 678 Fu Rong Road, Hefei, 230601, Anhui, China. tf172126@163.com.
Molecular Biology Reports
|January 12, 2020
Summary
The NLRC5 protein plays a dual role in cancer, potentially aiding immune evasion in some tumors but promoting progression in others. Further research is needed to determine its therapeutic potential in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Significant advancements have been made in understanding tumor progression and immune evasion mechanisms.
- The protein NLRC5 has emerged as a key regulator in cancer immunity.
- NLRC5 influences cancer immune escape by modulating MHC class I gene expression.
Purpose of the Study:
- To review the multifaceted role of NLRC5 in various tumor types.
- To investigate the potential of NLRC5 as a therapeutic target for cancer treatment.
Main Methods:
- Literature review of recent studies on NLRC5 in cancer.
- Analysis of NLRC5 expression patterns in different tumors.
- Evaluation of NLRC5's functional impact on tumor development and immune response.
Main Results:
- NLRC5 enhances MHC class I expression, contributing to immune evasion in certain cancers.
- Conversely, NLRC5 is upregulated in other tumors, promoting their development and progression.
- The specific role of NLRC5 appears context-dependent on the tumor type.
Conclusions:
- NLRC5 exhibits a complex and contradictory role in cancer progression and immune evasion.
- Targeting NLRC5 may offer a novel therapeutic strategy, but requires careful consideration of its dual functions.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.0K
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K